Nexalin Technology (NXL) Cash from Investing Activities Growth (1y) (2024 - 2026)
Nexalin Technology (NXL) Cash from Investing Activities Growth (1y) (2024 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.11 Bn | 194.51 Bn | 7.27 Bn | -15.64% |
| 2 | Stryker | 129.85 Bn | 126.37 Bn | 4.50 Bn | -514.42% |
| 3 | Medtronic | 119.93 Bn | 110.71 Bn | 6.41 Bn | -87.14% |
| 4 | Boston Scientific | 74.18 Bn | 73.64 Bn | 3.85 Bn | -73.71% |
| 5 | Edwards Lifesciences | 52.54 Bn | 48.29 Bn | 1.35 Bn | -12.26% |
| 6 | Dexcom | 34.76 Bn | 32.81 Bn | 830.00 Mn | 618.55% |
| 7 | GE HealthCare Technologies | 34.25 Bn | 32.14 Bn | 2.18 Bn | 48.43% |
| 8 | Koninklijke Philips | 26.45 Bn | 23.13 Bn | 4.55 Bn | 91.33% |
| 9 | Steris | 23.29 Bn | 22.80 Bn | 684.20 Mn | 0.00% |
| 10 | Nexalin Technology | 7.08 Mn | 6.07 Mn | 8,897.00 | 137.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 137.25% |
| Mar 31, 2026 | 2.44% |
| Dec 31, 2025 | -57.66% |
| Sep 30, 2025 | 136.25% |
| Jun 30, 2025 | -353.07% |
| Mar 31, 2025 | 102.07% |
| Dec 31, 2024 | 33.09% |
| Sep 30, 2024 | -639.66% |
| Jun 30, 2024 | 77.56% |
| Mar 31, 2024 | -52.23% |